Yucca Health GLP-1 Review (2026): Pricing, Coverage, and Tradeoffs

Item: Yucca Health
Author: RangeYourself

Yucca Health review, semaglutide compounded, $69/mo on the 12-month plan ($828 billed per term); $75/mo on the 6-month plan; $89/mo month-to-month. verified 2026-11-07., tirzepatide compounded, $119/mo on the 12-month plan ($1,428 billed per term); $125/mo on the 6-month plan; $139/mo month-to-month. verified 2026-11-07.. Low advertised entry price on compounded GLP-1 with plain FDA disclosures and all-50-state provider coverage. Independent 2026 review from RangeYourself.

By RangeYourselfLast verified 2026-11-07

Quick take

Yucca Health is compounded semaglutide and tirzepatide, once-weekly injection ('semaglutide+' / 'tirzepatide+'); also sells nad+ and sermorelin (out of registry scope), priced as 6-month prescription plans billed monthly/quarterly/6-month; advertised new-patient entry pricing; full pricing shared after intake. Best for: Low advertised entry price on compounded GLP-1 with plain FDA disclosures and all-50-state provider coverage. Watch out for: The $125/mo figure is the 6-month-commitment semaglutide rate ($750 billed every 6 months) and carries Yucca's own 'Exclusive Lifetime Offer, Coupon Auto-Applied' banner; 3-month is $140/mo and month-to-month is $146/mo. Yucca states 'Your price stays flat at every dose level' but publishes no per-dose price list. Per the refund page (read 2026-10-06) the order is final once a clinician issues the prescription. Pharmacies are not named.

Pricing summary

Price verified: 2026-11-07 (checked against the provider’s public pricing surface)
All-in monthly cost: $69/month (medication included), 12-month plan rate
Semaglutide: Compounded, $69/mo on the 12-month plan ($828 billed per term); $75/mo on the 6-month plan; $89/mo month-to-month. Verified 2026-11-07.
Tirzepatide: Compounded, $119/mo on the 12-month plan ($1,428 billed per term); $125/mo on the 6-month plan; $139/mo month-to-month. Verified 2026-11-07.
Compounded vs brand-name: Compounded only
Insurance accepted: No insurance-billing path published (cash-pay); confirm at signup
Consult type: Async questionnaire, per the provider’s published flow
Dose-escalation pricing: Yucca states on both product pages (verified 2026-10-06): 'Your price stays flat at every dose level.' and, in the plan-inclusions list, 'Same price, every dose. For life.' Plan-length prices: semaglutide $125/mo on 6 months, $140/mo on 3 months, $146/mo month-to-month; tirzepatide $225/mo on 6 months, $248/mo on 3 months, $258/mo month-to-month. No per-dose price list is published, so the flat claim is attribute-only.
Refund policy: Refunds & Cancellations page (updated September 17, 2026; read 2026-10-06): 'Once your prescription is issued, the order is final.' Before a prescription is issued the order can be cancelled for a full refund; a clinician decline returns every dollar; cancel at least 7 days before the scheduled renewal. Separately, the product pages advertise a 6-Month Promise refund program for plans started on or after September 18, 2026 ('It is not a medical guarantee'); its terms were not read in full.
States served: All 50 US states + Washington, D.C.

See Yucca Health pricing →

Choose Yucca Health if

You want a low advertised entry price on compounded semaglutide or tirzepatide
You value an upfront 'not FDA-approved' compounding disclosure in the FAQ
You want provider coverage in all 50 states with free 2-day shipping
You're comfortable confirming your exact ongoing rate at intake (pricing beyond the entry offer is shared after eligibility)

Skip Yucca Health if

You want a named dispensing pharmacy, published dose-tier pricing, insurance billing, or a brand-name (non-compounded) GLP-1.

Contraindications and clinical notes

Per Yucca's semaglutide page: 'not appropriate for everyone, including patients with certain thyroid cancer histories, MEN2, pregnancy, or allergy to semaglutide.'. Talk to a clinician about personal or family history of medullary thyroid carcinoma, MEN 2, pancreatitis, or other conditions before starting any GLP-1 medication.

How Yucca Health compares

Frequently asked questions

How much does Yucca Health cost per month?

Yucca Health's lowest verified rate is $69/month with compounded medication included, and that figure is its 12-month plan rate rather than a month-to-month price. Semaglutide: Compounded, $69/mo on the 12-month plan ($828 billed per term); $75/mo on the 6-month plan; $89/mo month-to-month. Verified 2026-11-07.; tirzepatide: Compounded, $119/mo on the 12-month plan ($1,428 billed per term); $125/mo on the 6-month plan; $139/mo month-to-month. Verified 2026-11-07.. Yucca states on both product pages (verified 2026-10-06): 'Your price stays flat at every dose level.' and, in the plan-inclusions list, 'Same price, every dose. For life.' Plan-length prices: semaglutide $125/mo on 6 months, $140/mo on 3 months, $146/mo month-to-month; tirzepatide $225/mo on 6 months, $248/mo on 3 months, $258/mo month-to-month. No per-dose price list is published, so the flat claim is attribute-only.

Does Yucca Health accept insurance?

Yucca Health publishes cash-pay prices and we found no insurance-billing path on its own site. Where a provider's own FAQ leaves the door open, the answer sits inside its intake flow, which we do not enter, so confirm at signup rather than treating this as settled. If you want insurance-billed brand-name GLP-1, see our list of GLP-1 programs that accept insurance.

What states does Yucca Health serve?

Yucca Health ships medication to all 50 US states plus Washington, D.C.

Is Yucca Health compounded or brand-name?

Yucca Health prescribes compounded semaglutide and tirzepatide via state-licensed 503A pharmacies or 503B outsourcing facilities. Compounded medication is not individually FDA-approved. The shortage-era compounding pathway ended after the FDA declared the semaglutide shortage resolved on February 21, 2025 and the tirzepatide shortage resolved in December 2024, so compounding now proceeds under the ordinary rules for individual patients.

What's the catch with Yucca Health?

The $125/mo figure is the 6-month-commitment semaglutide rate ($750 billed every 6 months) and carries Yucca's own 'Exclusive Lifetime Offer, Coupon Auto-Applied' banner; 3-month is $140/mo and month-to-month is $146/mo. Yucca states 'Your price stays flat at every dose level' but publishes no per-dose price list. Per the refund page (read 2026-10-06) the order is final once a clinician issues the prescription. Pharmacies are not named. Avoid if: you want a named dispensing pharmacy, published dose-tier pricing, insurance billing, or a brand-name (non-compounded) glp-1.

What the records show

Yucca Health's Trustpilot record is strong; we found no BBB listing to supplement it.

Trustpilot: 4.7★ (1,193 reviews) via Trustpilot, checked 2026-07-24

Independently observed third-party data, not our own editorial score. Full methodology: GLP-1 Provider Reliability Report.

Related guides

Yucca Health availability by state

GLP-1 programs in California , where Yucca Health ships and how it stacks up locally.
GLP-1 programs in Texas , where Yucca Health ships and how it stacks up locally.
GLP-1 programs in Florida , where Yucca Health ships and how it stacks up locally.
GLP-1 programs in New York , where Yucca Health ships and how it stacks up locally.
GLP-1 programs in Illinois , where Yucca Health ships and how it stacks up locally.

About compounded GLP-1 medicationsCompounded semaglutide and tirzepatide are not FDA-approved finished products. They are prepared by state-licensed 503A pharmacies or 503B outsourcing facilities and are not individually reviewed by the FDA for safety, effectiveness, or quality. Compounders describe these preparations as using the same active ingredient as the approved medicines; the FDA has warned that some compounded products use salt forms, semaglutide sodium or semaglutide acetate, that it considers different active ingredients from the approved drug, and has issued warning letters over marketing that presents a compounded preparation as interchangeable with an approved one. The FDA declared the semaglutide shortage resolved on February 21, 2025 and the tirzepatide shortage resolved in December 2024, so the shortage-era pathway for broad compounding of these drugs has ended. Compounding now proceeds under the ordinary rules: a 503A pharmacy compounding for an individual patient on a prescription, or a 503B outsourcing facility, which compounds in bulk under CGMP and FDA registration rather than per patient. Those rules generally do not cover a product that is “essentially a copy” of an approved drug unless a prescriber documents a change that makes a significant difference for an individual patient. Talk to a clinician about contraindications including personal or family history of medullary thyroid carcinoma or MEN 2. RangeYourself does not provide medical advice, does not guarantee a prescription, and does not guarantee weight-loss results.

About these products

These are compounded preparations, not FDA-approved for anti-aging or longevity indications, and a prescription from a licensed clinician is required. Compounding pharmacies are not individually reviewed by the FDA for the safety or effectiveness of a specific compounded product. We rank and describe these programs on price and access only, never on efficacy, outcomes, or benefit claims, and we do not repeat a provider’s own marketing claims as independently verified fact.

NAD+: NAD+ is not an FDA-approved drug, and its compounding status is not settled in its favor. In a warning letter to GenoGenix LLC dated January 20, 2026 (WL#718739), the FDA stated that NAD+ is not eligible for compounding by a 503B outsourcing facility. We could not identify a clear 503A pathway for it either: it has no USP monograph and is not a component of an approved drug. A Class I recall of an NAD+ injectable over endotoxin contamination is also on the record. We rank the programs on this page on published price only, and price is not a safety, quality, or eligibility signal here, confirm sourcing, the dispensing pharmacy, and any state restrictions directly with the provider before purchase, and discuss it with a prescribing clinician.

Sermorelin: not currently marketed as an FDA-approved product; it is compounded by licensed pharmacies for individual patients.

These peptide and longevity products are not identical to, and are never described here as generic or equivalent to, any FDA-approved drug, and unlike compounded GLP-1 medication most of them have no FDA-approved counterpart at all. State availability varies by provider and by product, several programs listed here disclose per-state restrictions; confirm eligibility in your state before purchase. RangeYourself does not provide medical advice and does not guarantee a prescription.

RangeYourself is reader-supported. We may earn a commission when you click on certain links, at no extra cost to you. Editorial recommendations are made independently. Pricing reflects publicly listed entry tiers verified on 2026-11-07 and may change.